Summary of Pro Pharmaceutical Conference Call Company Overview - **Company**: Pro Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on CDMO (Contract Development and Manufacturing Organization) services, API (Active Pharmaceutical Ingredients), and generic drugs Key Points CDMO Business Performance - CDMO revenue for the first three quarters reached **1.69 billion** yuan, a year-on-year increase of nearly **20%** [2][3] - Gross margin for CDMO improved to **44.4%**, up from **40.8%** the previous year [3] - The number of commercial projects increased by **15%**, clinical projects by **41%**, and quoted projects by **68%** [2][3] - The company plans to hire **400-500** new employees to support CDMO business expansion [2][5] API Market Conditions - The API market has entered a period of overcapacity since **2022**, with demand decreasing by **30-40%** and prices significantly dropping [2][6] - The company anticipates a gradual recovery in the API market by **2026**, although the recovery will be slow [6] - Current gross margin for API is around **20%**, expected to improve as capacity utilization increases [2][11] Generic Drug Market Challenges - The generic drug market is heavily impacted by national procurement policies, leading to continuous price declines [2][7] - The company is focusing on developing improved new drugs and accelerating globalization efforts, with products already sold in the U.S. market [2][7] Future Performance Outlook - The third quarter of **2025** is expected to be the lowest point for the year, with a rebound in demand anticipated in the fourth quarter [2][8] - Overall performance is expected to improve in **2026**, with various demands showing signs of recovery [9] Gross Margin Trends - Tmall business gross margin is approximately **44%**, expected to remain between **40-50%** [2][11] - The gross margin for intermediates may be affected due to self-operated RCM, while CDMO business is expected to maintain stable margins [11] - Textile drugs maintain a gross margin of **50-60%** [11] Customer Base and Market Expansion - The company has **670** CDMO customers, expected to grow to **750** by year-end [25] - The U.S. market is projected to account for about **40%** of future CDMO customers, with China at **30-35%** [14][15] Capacity and Production Plans - Current overall capacity utilization is around **40%**, primarily affected by API demand [16][17] - The company has made proactive capacity expansions to meet growing market demands [16] Research and Development - The company plans to recruit approximately **500** new R&D personnel to support project demands [19] - R&D expenses are expected to increase due to the high investment required in the CDMO sector [19] Currency Exchange Impact - Currency fluctuations are not a major concern, as the company has agreements to mitigate risks [20][21] Medical Aesthetics Business - The medical aesthetics segment is in its early stages, with expected revenue of only a few million yuan in **2025** [22] Revenue and Profitability - For the first three quarters, CDMO revenue was approximately **1.69 billion** yuan, while API and trade revenue totaled **5.2 billion** yuan [23] - The raw material segment has seen a decline of about **10%** year-on-year, primarily due to low-margin trade reductions [23][24] Future Product Development - The company plans to launch **10-15** new specialty API products annually, with a growth period expected in the next two to three years [26][27] Veterinary Medicine Market - Veterinary products like Florfenicol are currently at historical low prices, with supply exceeding demand [28] CMO Opportunities - The company is seeing some opportunities due to the overseas patent cliff, although these are not as abundant as in previous years [29]